RenovoRx Reports Record Q2 Revenue, Raises 2026 Guidance to $3.75M-$4.25M
RNXT sits 70% above its 52-week low of $0.701.
Summary
RenovoRx reported record Q2 2026 revenue of $909,000, raised full-year guidance, and announced full enrollment in its Phase III TIGeR-PaC trial.
Key Events · Earnings and Guidance · RNXT
-
Record Q2 Revenue
Revenue of $909,000 for Q2 2026, up 61% sequentially and 115% year-over-year, driven by accelerating commercial adoption of RenovoCath.
-
Raised 2026 Guidance
Full-year 2026 revenue guidance raised to $3.75M-$4.25M from prior $3.0M-$4.0M, implying 241%-286% year-over-year growth.
-
Phase III Trial Fully Enrolled
TIGeR-PaC trial in locally advanced pancreatic cancer reached full enrollment; completion expected H1 2027 with topline data in H2 2027.
-
Expansion Beyond Pancreatic Cancer
First commercial use of RenovoCath in a sarcoma patient, marking physician-driven expansion to other solid tumors.
Analysis · RNXT · Life Sciences
RenovoRx delivered record quarterly revenue of $909,000, up 61% sequentially and 115% year-over-year, and raised its full-year 2026 revenue guidance to $3.75M-$4.25M from $3.0M-$4.0M. The company also announced full enrollment in its Phase III TIGeR-PaC trial, with topline data expected in H2 2027, and the first commercial use of RenovoCath in a sarcoma patient, expanding beyond pancreatic cancer. Cash of $9.5M is sufficient to fund operations into H2 2027, but the company continues to burn cash with a net loss of $2.9M in Q2. The stock trades near $1.19, and the company faces a Nasdaq minimum bid price compliance deadline of December 28, 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNXT was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.5M. The 52-week trading range was $0.70 to $1.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.